Somryst® is the first and only prescription digital therapeutic indicated to treat chronic insomnia. Somryst is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia – CBT-I) to adults 22 years of age and older with chronic insomnia.

Pear Therapeutics, Inc. is a venture-backed digital health company focused on the development of digital therapies and drug/software combinations to treat diseases with high unmet medical need.  PEAR's patented, clinically validated approach is designed to provide enhanced outcomes for patients, actionable data for clinicians, and cost-effective solutions for payers.

Somryst provides a clinician facing dashboard that allows healthcare providers to track patient treatment and progress. The clinician dashboard displays information about patients’ use of Somryst, including the Insomnia Severity Index (ISI)1, the Patient Health Questionnaire 8 (PHQ-8)2 scores, and sleep metrics derived from nightly sleep diaries.